請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74599
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李明學 | |
dc.contributor.author | Ta-Li Yen | en |
dc.contributor.author | 閻大立 | zh_TW |
dc.date.accessioned | 2021-06-17T08:44:58Z | - |
dc.date.available | 2024-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-06 | |
dc.identifier.citation | 1. Paoloni-Giacobino. A, Chen. H, Peitsch. MC, Rossier. C, Antonarakis. SE. Cloning of the TMPRSS2 Gene, Which Encodes a Novel Serinr protease with transmembrane, LDLRA, and SPCR domains and Maps to 21q22.3. Genomics 1997;44:309-20.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 3. 2016 癌症登記報告 台灣. 衛生福利部國民健康署 2016. 4. Peter C. Albertsen M, James A. Hanley P, Donald F. Gleason M, Michael J. Barry M. Competing Risk Analysis of Men aged 55 to 74 years af diagnosis managed conservatively for clincially localized prostate cancer. JAMA 1998;280:980. 5. Gerald W. Chodak M, John Warner M. Results of conservative management of clincially localized prostate cancer. The New England Journal of medicine 1994;330:242-8. 6. CUNHA GR. The Role of Androgens in the Epithelio-mesenchymal interactions Involved in Prostatic Morphogenesis in Embryonic mice. ANAT REC 1977;175:87-96. 7. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 2010;12:639-57. 8. Kim. YS, Alarcon. SV, Lee. S, Lee. M-J, Giaccone L, Neckers JB. Update on Hsp90 inhibitors in clincial traial. Current topics in medicinal chenistry 2009;9:1479-92. 9. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 2013;140:223-38. 10. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004;93:233-41. 11. Shang Y, Myers M, Brown M. Formation of the Androgen Receptor Transcription Complex. Molecular Cell 2002;9:601-10. 12. LUKE. MC, COFFEY. DS. Human Androgen Receptor Binding to the Androgen Response Element of Prostate Specific Antigen. Journal of Andrology 1994;15:41-51. 13. Lin. B, Ferguson. C, White. JT, et al. Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serinr Proteases TMPRSS2. Cancer research 1999;59:4180-4. 14. Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010;5:e13500. 15. Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol 2010;28:e408. 16. Woods BS, Sideris E, Sydes MR, et al. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer: Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.Eur Urol Oncol 2018;1:449-58. 17. Tsao CK, Cutting E, Martin J, Oh WK. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol 2014;6:97-104. 18. Scher HI, Cabot RC, Harris NL, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine 2012;367:1187-97. 19. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. The Lancet 2010;375:1437-46. 20. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95. 21. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-70. 22. Rakash S. Role of proteases in cancer: A review. Biotechnology and Molecular Biology Reviews 2012;7:90-101. 23. Mason SD, Joyce JA.Proteolytic networks in cancer.TrendsCell Biol 2011;21:228-37. 24. Lopez-Otin C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008;283:30433-7. 25. Puente XS, nchez LMS, ndez Gr-F, Velasco G, pez-Otı´n CL. A genomic view of the complexity of mammalian proteolytic systems. Biochemical Society Transactions 2005;33:331-4. 26. Quesada V, Ordonez GR, Sanchez LM, Puente XS, Lopez-Otin C. The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res 2009;37:D239-43. 27. Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. J Biol Chem 2009;284:23177-81. 28. Antalis TM, Buzza MS, Hodge KM, Hooper JD, Netzel-Arnett S. The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J 2010;428:325-46. 29. Szabo R, Bugge TH. Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 2008;40:1297-316. 30. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000;275:26333-42. 31. Jiang J, Yang J, Feng P, et al. N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding. J Biol Chem 2014;289:19500-7. 32. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6:185-95. 33. Afar DEH, Vivanco I, Hubert RS, et al. Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease Results in Its Secretion by Prostate and Prostate Cancer Epithelia. Cancer research 2001;61:1686-92. 34. Guipponi. M, Vuagniaux. Gg, Wattenhofer. M, et al. The transmembrane serine protease (TMPRSS3) mutated in deafness DFNB8/10 activates the epithelial sodium channel (ENaC) in vitro. Human Molecular Genetics 2002;11. 35. Stallmach R, Gloor SM. Neurobin/TMPRSS11c, a novel type II transmembrane serine protease that cleaves fibroblast growth factor-2 in vitro.Biochem J2008;412:81-91. 36. LOUVARD. D, S. MAROUX J, BARATTI., DESNUELLE. P. On the distribution of Enterokinase in porcine intestine and on its subcellular localization. Biochimica et Biophysica Acta 1973;309:127-37. 37. Fonseca. P, Light. A. The Purification and Characterization of the Bovine Enterokinase from Membrane Fragments in the Duodenal Mucosal Fluid. Biochem J 1983;258:14516-20. 38. Lin. C-Y, Anders. J, Johnson. M, Sang. QA, Dickson. RB. Molecular Cloning of cDNA for Matriptase, a matrix-degrading serine protease with trypsin-like activity. Biochem J 1999;274:18231-6. 39. Yamaoka. K, Masuda. K-i, Ogawa. H, Takagi. K-i, Umemoto. N, Yasuoka. S. Cloning and characterization of the cDNA for Human Airway Trypsin-like Proteases. Biochem J 1998;273:11895-901. 40. Wu SR, Cheng TS, Chen WC, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol 2010;177:3145-58. 41. Kiyomiya K, Lee MS, Tseng IC, et al. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol 2006;291:C40-9. 42. Bergum C, List K. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression. Prostate 2010;70:1422-8. 43. Tanabe LM, List K. The role of type II transmembrane serine protease-mediated signaling in cancer. FEBS J 2017;284:1421-36. 44. Lucas JM, True L, Hawley S, et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 2008;215:118-25. 45. Chen YW, Lee MS, Lucht A, et al. TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am J Pathol 2010;176:2986-96. 46. WILSON. S, GREER. B, HOOPER. J, et al. The membrane-anchored serinr protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005;388:967-72. 47. Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov 2014;4:1310-25. 48. Ko CJ, Huang CC, Lin HY, et al. Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis. Cancer Res 2015;75:2949-60. 49. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511. 50. St John J, Powell K, Conley-Lacomb MK, Chinni SR. TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression. J Cancer Sci Ther 2012;4:94-101. 51. Mwamukonda K, Chen Y, Ravindranath L, et al. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status. Prostate Cancer Prostatic Dis 2010;13:47-51. 52. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-88. 53. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res 2009;69:6027-32. 54. Garcia-Perdomo HA, Chaves MJ, Osorio JC, Sanchez A. Association between TMPRSS2:ERG fusion gene and the prostate cancer: systematic review and meta-analysis. Cent European J Urol 2018;71:410-9. 55. Bottcher-Friebertshauser E, Klenk HD, Garten W. Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium. Pathog Dis 2013;69:87-100. 56. Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie 2017;142:1-10. 57. Cheng Z, Zhou J, To KK, et al. Identification of TMPRSS2 as a Susceptibility Gene for Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza. J Infect Dis 2015;212:1214-21. 58. Kuhn N, Bergmann S, Kosterke N, et al. The Proteolytic Activation of (H3N2) Influenza A Virus Hemagglutinin Is Facilitated by Different Type II Transmembrane Serine Proteases. J Virol 2016;90:4298-307. 59. Sakai K, Tahara M, et al. The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses. J Virol 2014;88:5608-16. 60. Winer A, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther 2018;17:1147-55. 61. Xuan JA, Schneider D, Toy P, et al. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res 2006;66:3611-9. 62. Farady. CJ, Sun. J, Darragh. MR, Miller. SM, Craik. CS. The Mechanism of inhibition of Antibody-Based inhibitors of Membrane-Type Serinr Protease 1 (MT-SP1). J Mol Biol 2007;369:1041-51. 63. Tamberg T, Hong Z, De Schepper D, et al. Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors. J Biol Chem 2019;294:314-26. 64. Petersen. HH, Hansen. M, Schousboe. SL, Andreasen. PA. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator. Eur J Biochem 2001;268:4430-9. 65. Sgier D, Zuberbuehler K, Pfaffen S, Neri D. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. Protein Eng Des Sel 2010;23:261-9. 66. Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM. Allosteric effects of a monoclonal antibody against thrombin exosite II. Biochemistry 1998;37:15057-65. 67. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.Br J Clin Pharmacol 2011;72:553-62. 68. Ganesan R, Eigenbrot C, Kirchhofer D. Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochem J 2010;430:179-89. 69. F.Martin., C.Volpari., hler. CS, et al.Affinity selection of a camelized VH domain antibody inhibitor of hepatitis C virus NS3 protease.ProteinEngineering1997;10:607-14. 70. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78. 71. Herrala. AM, Porvari. KS, nen. APK, Vihko. PT. Comparison of Human Prostate Specific Glandular Kallikrein 2 and Prostate Specific Antigen Gene Expression in Prostate with Gene Amplification and Overexpression of Prostate Specific Glandular Kallikrein 2 in Tumor Tissue. CANCER 2001;92. 72. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005;63:324-9. 73. Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol 2012;3:120-9. 74. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012;4:127rv3. 75. Afar. DEH, Vivanco. I, Hubert. RS, et al. Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease Results in Its Secretion by Prostate and Prostate Cancer Epithelia. Cancer research 2001;61:1686-92. 76. Zhang MY, Wang Y, Mankowski MK, Ptak RG, Dimitrov DS. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 2009;27:857-63. 77. Chen H, Xu X, Jones IM. Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology 2007;4:33. 78. Pleass RJ. Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol 2009;31:529-38. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/74599 | - |
dc.description.abstract | 雄性激素的訊息傳遞及細胞周圍的蛋白水解作用在攝護腺癌的進程及轉移過程中,扮演重要的角色。其中我們對第二型嵌膜絲胺酸蛋白酶II (TMPRSS2)有高度的興趣,因為先前的研究中發現第二型嵌膜絲胺酸蛋白酶II可以透過活化它的蛋白酶疉層和細胞外基質的水解,促進攝護腺癌細胞侵襲、腫瘤生長及轉移。此外,第二型嵌膜絲胺酸蛋白酶II亦被報導有外泌或脫落(shed)的現象。因此,第二型嵌膜絲胺酸蛋白酶II在攝護腺癌的臨床應用上,具有診斷及作為治療標的的潛力。我的研究致力於建立抗第二型嵌膜絲胺酸蛋白酶II的抗體,並鑑尋出具攝護腺癌診斷及治療潛力的多株或單株抗體。我首先建立了穩定表達外泌型第二型嵌膜絲胺酸蛋白酶II重組蛋白的中國倉鼠卵巢細胞株,從其細胞的培養基中純化出此重組蛋白質並以此純化蛋白質作為免疫動物的抗原。我已從被抗原免疫過的天竺鼠和兔子製作出多株抗體及免疫小鼠製備單株抗體。抗第二型嵌膜絲胺酸蛋白酶II之天竺鼠源多株抗體可成功辨識第二型嵌膜絲胺酸蛋白酶的水解作用區塊。兔源多株抗體(Rabbi anti-TM2 pAb)具有良好的專一性,但其中和抑制第二型嵌膜絲胺酸蛋白酶II重組蛋白活性的能力,較不明顯。我們用兔源多株抗體可在攝護腺癌細胞培養基中以及在攝護腺癌病人的尿液檢體中偵測到分泌型的第二型嵌膜絲胺酸蛋白酶II。未來要利用兔源多株抗體建立ELISA,大量分析攝護腺癌病人尿液中第二型嵌膜絲胺酸蛋白酶II的含量,探討其作為攝護腺癌進程指標的潛力。在建立鼠源單株抗體的方面,經過細胞融合瘤的實驗,我初步得到一株可以辨認第二型嵌膜絲胺酸蛋白酶II重組蛋白的單株抗體融合瘤,並將釐清其應用於臨床的潛力。同時我們正在努力建立更多鼠源單株抗體,期望未來可以挑選到具中和第二型嵌膜絲胺酸蛋白酶II活性的單株抗體,以應用於臨床診斷或治療。 | zh_TW |
dc.description.abstract | Androgen signaling and pericellular proteolysis play important roles in prostate cancer (PCa) progression and metastasis. Among them, type II transmembrane serine proteases II (TMPRSS2) receives an attention because we found that TMPRSS2 could promote PCa cells invasion, tumor growth and metastasis through activation of its proteolytic cascade and extracellular matrix degradation. TMPRSS2 has been also reported to be shed out from cells after its activation. Thus, TMPRSS2 may serve as a biomarker for PCa diagnosis/prognosis and a therapeutic target in PCa. In this thesis, I aimed to generate anti-TMPRSS2 antibodies with a potential of diagnosis, prognosis or therapeutic usages. I used a mammalian secretory expression system to express recombinant TMPRSS2 proteins in CHO cells and purify those proteins from the conditioned media. I successfully used the purified rTMPRSS2 to be antigens for polyclonal antibody generation from a guinea pig and a rabbit. Guinea pig anti-TM2 antibody could recognize the protease domain of TMPRSS2. Rabbit anti-TM2 polyclonal antibody showed a great specificity against TMPRSS2 in cell lysates and could also recognize the shed TMPRSS2 in the conditioned media of PCa cells and PCa patients’ urine samples. The establishment of neutralizing monoclonal antibodies against TMPRSS2 are still undergoing. Thus, the results together indicate that the anti-TM2 antibodies are successfully generated from the animals of guinea pig and rabbit with a potential of clinical application. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:44:58Z (GMT). No. of bitstreams: 1 ntu-108-R06442004-1.pdf: 2097867 bytes, checksum: 9f957b5cbfe97abed746edfebd1605c2 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii ABSTRACT iii Chapter 1 Introduction. 1 1.1 Prostate cancer 2 1.2 Androgen signaling in prostate 2 1.3 Prostate cancer treatment. 3 1.4 Cancer metastasis and pericellular proteolysis 4 1.5 Type II transmembrane serine protease family 5 1.6 Type II transmembrane serine protease II (TMPRSS2) 7 1.7 The development of protease inhibitors 10 1.8 PSA and prostate cancer biomarker. 11 1.9. Shedding or secreting forms of TMPRSS2 and its application in PCa detection. 12 1.10 The purpose of this study 13 Chapter 2 Materials and methods. 15 2.1 Cell culture 16 2.2 Recombinant TMPRSS2 protein expression 16 2.3 TMPRSS2 recombinant protein purification 17 2.4 TMPRSS2 proteolytic assay 18 2.5 Antigen preparation of recombinant TMPRSS2 S441A proteins. 19 2.6 Rabbit and guinea pig Anti-TMPRSS2 polyclonal antibody generation. 19 2.7 Biotinylation of Rabbit anti-TM2 polyclonal antibody 20 2.8 Mouse Anti-TMPRSS2 monoclonal antibody generation 20 2.9 Indirect ELISA 21 2.10 Western blot 22 2.11 Dot blot analysis 23 2.12 Immunoprecipitation assay 23 Chapter 3 Results. 26 3.1 Establishment of the stable clones of CHO cells with the overexpression of recombinant wild type TMPRSS2 proteins and S441A mutant TMPRSS2 proteins. 27 3.2 Generation and purification of wild-type and S441A rTMPRSS2 proteins from the conditioned media of CHO cells. 29 3.3 Characterization of purified rTMPRRS2 and S441A rTMPRSS2 proteins and antigen preparation. 31 3.4 Characterization of guinea pig and rabbit anti-TMPRSS2 polyclonal antibodies. 34 3.5 Rabbit anti-TM2 and Guinea anti-TM2 polyclonal antibody applications. 36 3.6 Generation of Anti-TM2 mouse monoclonal antibodies. 39 Chapter 4 Figures. 41 Figure 1. Generation of stable clones of CHO cells with the expression of wild-type TMPRSS2 and S441A TMPRSS2 recombinant proteins. 42 Figure 2. Generation and purification of wild-type and S441A-mutant TMPRSS2 recombinant proteins from the conditioned media. 45 Figure 3.Characterization of purified rTMPRRS2 and S441A rTMPRSS2 proteins. 47 Figure 4. Characterization of guinea pig and rabbit anti-TMPRSS2 polyclonal antibodies. 50 Figure 5. Characterization of the effects of GP-anti TM2 and Rabbit-anti-TM2 pAb on the proteolytic activity of TMPRSS2. 52 Figure 6. Detection of TMPRSS2 proteins in the conditioned media of HEK293A, LNCaP and TMPRSS2-overexpressing LNCaP cells using AL20 monoclonal anti-TMPRSS2 antibody and biotinylated Rabbit anti-TM2 polyclonal antibody. 55 Figure 7. Detection of TMPRSS2 in prostate cancer patients’ urine samples using biotinylated Rabbit anti-TM2, Rabbit anti-TM2 polyclonal antibodies and AL20 monclonal anti-TM2 antibodies. 56 Figure 8. Mouse anti-TMPRSS2 monoclonal antibodies production. 57 Chapter 5 Discussion. 59 Chapter 6 Reference. 66 | |
dc.language.iso | en | |
dc.title | 建立抗第二型嵌膜絲胺酸蛋白酶II的診斷和治療性抗體及其在攝護腺癌症的應用 | zh_TW |
dc.title | Establishment of anti-TMPRSS2 antibody for diagnostic and treatment in prostate cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 張震東,張世宗,蕭培文 | |
dc.subject.keyword | 攝護腺癌,細胞外基質水解,第二型嵌膜絲胺酸蛋白?II,偵測性多株抗體,中和性單株抗體, | zh_TW |
dc.subject.keyword | prostate cancer,pericellular proteolysis,type II transmembrane serine protease II,polyclonal antibody,neutralizing antibody, | en |
dc.relation.page | 72 | |
dc.identifier.doi | 10.6342/NTU201902200 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.05 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。